According to TipRanks, Abrahams is a 5-star analyst with an average return of 14.5% and a 54.40% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Biogen, and Neurocrine.
In addition to RBC Capital, Gilead Sciences also received a Hold from Goldman Sachs’s Salveen Richter in a report issued on July 20. However, on July 23, BMO Capital assigned a Buy rating to Gilead Sciences (NASDAQ: GILD).
Based on Gilead Sciences’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $6.96 billion and a net profit of $2.02 billion. In comparison, last year the company earned a revenue of $6.67 billion and had a net profit of $1.32 billion
